Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
Holding IFRX?
Track your performance easily
IFRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $2.82
Previous CloseN/A
Volume66.97K
Average Volume (3M)288.62K
Market Cap
$149.56M
Enterprise Value$26.49M
Total Cash (Recent Filing)$29.12M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 20, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding58,883,270
10 Day Avg. Volume190,478
30 Day Avg. Volume288,617
Standard Deviation0.32
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2312.18
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-56.45
Enterprise Value/Ebitda-3.71
Forecast
1Y Price Target
$9.00Price Target Upside254.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
InflaRx News
PremiumCompany Announcements
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS
PremiumCompany Announcements
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug
PremiumCompany Announcements
InflaRx Gets EMA Nod for COVID-19 Treatment
PremiumCompany Announcements
InflaRx Reports Q3 2024 Financial Results and ProgressBulls Say, Bears Say
Bulls Say
Clinical SuccessGohibic treatment demonstrated improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set.
Financial StabilityIFRX ended with €62.0M, expected to fund operations into 2026.
Regulatory ApprovalThe European Commission granted marketing authorization under exceptional circumstances for Gohibic for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome, making it the only treatment approved in the EU for this condition.
Bears Say
Commercialization ChallengesThe path to commercialization and the magnitude of the opportunity for Gohibic are unclear.
Regulatory HurdlesThe FDA indicated that InflaRx would need to conduct an additional well-controlled and adequately powered study in a broader ARDS setting for it to obtain a BLA.
Sales PerformanceSales of Gohibic have materialized slower than expected.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.16% Other Institutional Investors
99.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IFRX FAQ
What was InflaRx NV’s price range in the past 12 months?
InflaRx NV lowest stock price was $1.17 and its highest was $2.81 in the past 12 months.
What is InflaRx NV’s market cap?
InflaRx NV’s market cap is $149.56M.
When is InflaRx NV’s upcoming earnings report date?
InflaRx NV’s upcoming earnings report date is Mar 20, 2025 which is in 55 days.
How were InflaRx NV’s earnings last quarter?
InflaRx NV released its earnings results on Nov 08, 2024. The company reported -$0.309 earnings per share for the quarter, missing the consensus estimate of -$0.258 by -$0.052.
Is InflaRx NV overvalued?
According to Wall Street analysts InflaRx NV’s price is currently Undervalued.
Does InflaRx NV pay dividends?
InflaRx NV does not currently pay dividends.
What is InflaRx NV’s EPS estimate?
InflaRx NV’s EPS estimate is -0.25.
How many shares outstanding does InflaRx NV have?
InflaRx NV has 58,883,270 shares outstanding.
What happened to InflaRx NV’s price movement after its last earnings report?
InflaRx NV reported an EPS of -$0.309 in its last earnings report, missing expectations of -$0.258. Following the earnings report the stock price went up 3.311%.
Which hedge fund is a major shareholder of InflaRx NV?
Currently, no hedge funds are holding shares in IFRX
---
InflaRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (254.33% Upside)
$9.00 (254.33% Upside)
Hedge Fund Trend
Decreased
By 173.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.79%
12-Months-Change
Fundamentals
Return on Equity
-86.59%
Trailing 12-Months
Asset Growth
-35.13%
Trailing 12-Months
Company Description
InflaRx NV
InflaRx (IFRX) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative anti-inflammatory therapeutics by targeting the complement system. The company operates within the biotechnology and pharmaceutical sectors, with its core product being vilobelimab, an anti-C5a monoclonal antibody designed to treat a variety of inflammatory diseases. InflaRx aims to address critical unmet medical needs in conditions such as hidradenitis suppurativa, ANCA-associated vasculitis, and COVID-19 related complications.
---
IFRX Stock 12 Month Forecast
Average Price Target
$9.00
▲(254.33% Upside)
Technical Analysis
Amgen
―
Biogen
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering IFRX
1 Year
1 Year Success Rate
15/28 ratings generated profit
1 Year Average Return
+15.29%
reiterated a buy rating 8 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 53.57% of your transactions generating a profit, with an average return of +15.29% per trade.
---